Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
*All peptide sales are nonrefundable and nonreturnable
BPC-157 Dosing in Hepatic Impairment: Evidence, Risks, and Clinical Guidance At a glance No FDA-approved formulation / BPC-157 is available only through 503A compounding pharmacies Zero published human RCTs evaluating BPC-157 in hepatic impairment populations Animal models show hepatoprotective effects against NSAID, alcohol, and toxin-induced liver damage Standard compounded dose range is 200-500 mcg/day subcutaneously or intramuscularly Suggested starting dose in hepatic impairment is 200-250 mcg/day subcutaneously Peptides are cleared primarily by proteolytic degradation, not hepatic CYP450 metabolism Liver enzyme monitoring (ALT, AST, bilirubin) recommended at baseline and every 2-4 weeks BPC-157 has shown cytoprotective effects on gastric and intestinal mucosa in over 20 animal studies The FDA has not established hepatic dosing adjustments for BPC-157 Cycle length in liver-compromised patients: 4-6 weeks with reassessment before continuation What Is BPC-157 and How Does It Work
By combining localized and systemic regenerative support, BPC-157 / TB-500 may offer several wellness-focused benefits, including: 1
Any weight loss likely results from concurrent dietary modifications rather than the injections themselves
TB-500 represents an intriguing area of emerging clinical application for long COVID patients dealing with any of the following concerns: Neurological symptoms Cognitive impairment Tissue damage associated with prolonged inflammation KPV and Immune-Gut Axis Modulation KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH) with potent anti-inflammatory effects, particularly in the gut
Riggle PJ, Kumamoto CA
